Delcath Systems Charts Profitable Path Amid Heavy Investment

Delcath Systems, Inc. ((DCTH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Delcath Systems used its latest earnings call to paint a picture of a company in transition from niche operator to scaled rare‑oncology platform. Management highlighted record 2025 revenue, robust procedure growth, solid profitability and a cash‑rich, debt‑free balance sheet, while openly flagging that heavy investment, seasonality and pricing mix could pressure margins and quarterly results over the next few years.

Strong Volume Growth and Record Revenue

Delcath posted more than 40% procedure volume growth in 2025, driving record full‑year revenue of $85.2 million. Hepzato contributed $78.8 million and ChemoSAT $6.4 million, with Q4 Hepzato revenue climbing to $19.0 million from $13.7 million a year earlier, an increase of roughly 39%.

Profitability and Cash-Rich Balance Sheet

The company swung to a 2025 net profit of $2.7 million from a $26.4 million loss in 2024, and full‑year adjusted EBITDA improved to $25.1 million from a $2.5 million loss. Delcath ended the year with about $91 million in cash and investments, no debt, no warrants and generated $22.5 million in full‑year operating cash flow.

Expanding Commercial Footprint

Delcath now operates 28 active REMS‑certified treatment centers and aims to reach around 40 by 2026, expanding access for ultra‑orphan patients. Early 2026 data show new patient starts per site per month rising to about 0.75 from a 2025 average of 0.5, while average treatments per patient remain near four cycles.

CHOPIN Data as a Key Commercial Catalyst

Management spotlighted the CHOPIN Phase 2 investigator‑initiated study as a potential game‑changer for Hepzato. The data reportedly show statistically significant and clinically meaningful gains in one‑year progression‑free survival, overall survival and response rates when Hepzato is sequenced with ipilimumab and nivolumab versus PHP alone.

Margin Strength and ASP Framework

Gross margin remained a standout, coming in at 85% in Q4 and 86% for the full year, reflecting the high‑value nature of Hepzato. For 2026, Delcath expects gross margins between 84% and 87% and is modeling an average selling price of roughly $175,000 per Hepzato kit, about a 10% discount to the list price.

Progress in Clinical Development Pipeline

The metastatic colorectal cancer trial is on track to have nearly all roughly 26 sites activated by mid‑2026, with interim data expected in late 2027, underscoring a long development runway. In metastatic breast cancer, Delcath plans to activate about 15 trial sites by late 2026 and is weighing additional immune checkpoint inhibitor combinations with build plans over the next three to six months.

Share Buybacks Signal Capital Discipline

Alongside reinvestment in growth, the company has started returning capital to shareholders via buybacks. Delcath repurchased 628,572 common shares for $6.0 million under its authorized $25 million share repurchase program, signaling confidence in its long‑term valuation.

Operating Expenses Surge as Investment Ramps

Growth comes at a cost, with full‑year SG&A rising to $43.0 million from $29.6 million and R&D more than doubling to $29.2 million from $13.9 million. Management expects R&D to increase nearly 90% in 2026 and SG&A to climb almost 50%, with Q1 SG&A alone running 30% to 40% above Q4.

Quarterly EBITDA Softness Highlights Near-Term Pressure

Despite strong full‑year profitability, Q4 2025 non‑GAAP adjusted EBITDA fell to $2.4 million from $4.6 million in the prior‑year quarter, a decline of about 48%. The drop underscores how rising operating expenses and investment ahead of revenue can compress margins on a quarter‑to‑quarter basis.

Seasonality and Site Capacity Volatility

Management cautioned that procedure volumes can be lumpy because of summer seasonality and staffing limits at REMS‑certified centers. With an ultra‑orphan patient base, even small shifts in patient numbers or local capacity can cause flat or modest growth between quarters, particularly in the third quarter.

Pricing Mix and 340B Discount Uncertainty

Delcath’s revenue guidance assumes an effective average Hepzato discount of roughly 10%, but actual realized pricing may vary significantly each quarter. The company’s concentrated customer base and changing 340B eligibility mix mean revenue per kit may swing, introducing additional volatility into near‑term top‑line trends.

Complex Clinical Timelines and Enrollment Risk

Device‑based oncology trials remain operationally complex, raising execution risk and stretching timelines for key readouts. Interim data from the mCRC trial are not expected until late 2027, while mBC activation and potential combination trials could face delays as the company spends three to six months refining study designs.

Reliance on CHOPIN Uptake and Referral Networks

Delcath’s commercial outlook is closely tied to rapid publication and adoption of CHOPIN data, which management believes will support future guidelines. However, many uveal melanoma patients are diagnosed outside PHP centers, and building referral networks amid competing trials like IDEA remains an execution challenge.

Forward-Looking Guidance and Outlook

For 2026, Delcath guided to at least $100 million in revenue, implying more than 20% growth in Hepzato kit procedures and over 10% growth for ChemoSAT. The company expects 84%–87% gross margins, about $175,000 average kit pricing, a ramp to roughly 40 active treatment centers and heavier R&D and SG&A spending funded by its strong cash position.

Delcath’s earnings call portrayed a company successfully crossing into profitability while deliberately stepping back on the accelerator to fund a broader oncology platform. For investors, the story combines strong top‑line momentum and high margins with real risks around spending, clinical timelines and execution, making 2026 a pivotal year to validate the bullish long‑term thesis.